The FDA has authorized for commercial use a wearable device for continuous monitoring of ketone and glucose levels in patients with diabetes aged at least 2 years, the agency and Abbott announced. The device (Libre Duo 10 Day system, Abbott Diabetes) is the first in the world to continuously monitor both ketone and glucose and the first in the U.S. approved to continuously monitor ketone levels,

System offers real-time diabetic ketoacidosis warnings

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes